NIKKI NAZWORTH: Open Payments
NPI 1992068084 · ABILENE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$563 in 32 payments from 10 companies in 2025. Trend: 2023 $420 · 2024 $554 · 2025 $563
Food & beverage: $563
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $180 |
| Neurocrine BioSciences, Inc. | 4 | $87 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $40 |
| Alkermes, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: VRAYLAR, INGREZZA, REXULTI, FANAPT, Auvelity, CAPLYTA, AUSTEDO XR, ARISTADA.
Industry payments across TX — which companies pay providers there.
